Biogen Reports Phase 2 Data for Cabotegravir in Atrial fibrillation

Biogen today announced Phase 2 results for Cabotegravir in patients with Atrial fibrillation. The study demonstrated that Cabotegravir improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Atrial fibrillation and support the continued development of Cabotegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Cabotegravir was consistent with previous observations, with no new safety signals identified.